Login
Navigate Fool.com
Will CHTP beat
the market?
Community Rating: 1 Star: Ominous

4.91 -0.14 (-2.77%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.08
Previous Close $5.05
Daily Range $4.75 - $5.10
52-Week Range $1.68 - $6.83
Market Cap $385.1M
P/E Ratio -21.04
Dividend (Yield) $0.00 (0.0%)
Volume 645,518
Average Daily Volume 3,006,712
Current FY EPS -$0.34

How do you think CHTP
will perform against the market?

Top CHTP Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted September 23, 2011

CAPS gypped me out of my sub-4 Chelsea pick last month so I closed it for a positive score, knowing market volatility would give me another opportunity. I expect Chelsea to submit the NDA for Northera … More

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted December 21, 2010

Chelsea is shooting up today on word that the company plans to submit the NDA for Northera for orthostatic hypotension in early 2011. The street seems to have interpreted this decision, coming after a … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Impax Breathes New Life Into Stalled Parkinson's Drug

Impax's (IPXL) stumbles in bringing Rytary, it's long lasting Parkinson's drug, to market may finally be over given its re-filed with the FDA for approval.

Why You Should Still Be Considering A Bio-Tech Stock, But With A Sensible Hedge

Does Mannkind Offer a Good Risk to Reward Ratio?

MannKind Corp.'s regulatory review for Afrezza is close at hand. Does the stock offer a favorable risk to reward profile?

Better Buyout Candidate: Chelsea Therapeutics International Ltd. vs. InterMune Inc.

A Foolish look at two top buyout candidates in the health care sector.

Mid-Afternoon Market Update: Markets Sell Off as Fuel Cell Names Turn to the Upside Once Again

This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!

A $25 billion buyout, a long-awaited FDA approval, two positive clinical studies, and one biopharma losing 37% of its value, are this week's top biotech stories.

3 Humongous Health-Care Stocks This Week

Find out which healthcare stocks deserved gold medals this week.

Chelsea Therapeutics International Ltd: FDA Approval Just the First Hurdle

Chelsea's Northera finally gets the nod from regulators, but whether anyone prescribes it remains to be seen.

3 Stocks Soaring Higher on These Drug Successes

Three stocks hitting the ceiling today, and the drugs that put them there.

Why Zale, Chelsea Therapeutics, and Nabors Industries Are Today's 3 Best Stocks

The S&P 500 finally succumbs to weak housing data while Zale, Chelsea Therapeutics and Nabors Industries all soar by double-digits.

See More CHTP News...

Sector

Healthcare

Industry

Drugs

Chelsea Therapeutics International Ltd. (CHTP) Description

A development stage pharmaceutical company that seeks to acquire and develop innovative products for the treatment of a variety of human diseases. Website: http://www.chelseatherapeutics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks